[go: up one dir, main page]

WO2000066774A3 - Analyse amelioree et ses reactifs - Google Patents

Analyse amelioree et ses reactifs Download PDF

Info

Publication number
WO2000066774A3
WO2000066774A3 PCT/GB2000/001639 GB0001639W WO0066774A3 WO 2000066774 A3 WO2000066774 A3 WO 2000066774A3 GB 0001639 W GB0001639 W GB 0001639W WO 0066774 A3 WO0066774 A3 WO 0066774A3
Authority
WO
WIPO (PCT)
Prior art keywords
assays
viral
methods
samples
reagents
Prior art date
Application number
PCT/GB2000/001639
Other languages
English (en)
Other versions
WO2000066774A2 (fr
Inventor
Edward Duncan Blair
Laurence Henry Robinson
Barbara Wendy Snowden
Sylvia Margaret Tisdale
Original Assignee
Glaxo Group Ltd
Edward Duncan Blair
Laurence Henry Robinson
Barbara Wendy Snowden
Sylvia Margaret Tisdale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Edward Duncan Blair, Laurence Henry Robinson, Barbara Wendy Snowden, Sylvia Margaret Tisdale filed Critical Glaxo Group Ltd
Priority to AU45867/00A priority Critical patent/AU4586700A/en
Priority to EP00927464A priority patent/EP1226270A2/fr
Priority to JP2000615396A priority patent/JP2002542804A/ja
Publication of WO2000066774A2 publication Critical patent/WO2000066774A2/fr
Publication of WO2000066774A3 publication Critical patent/WO2000066774A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des méthodes de génération de virus recombinants à partir d'échantillons, tels que des échantillons de virus non caractérisés ou des échantillons cliniques, l'utilisation dans des analyses des virus ainsi générés, principalement en vue de détecter une sensibilité virale altérée à des médicaments antiviraux. L'invention concerne également des réactifs, et plus particulièrement des constructions de vecteurs d'acide désoxyribonucléique (ADN), destinés à être utilisés dans ces méthodes et analyses. Les analyses sont conçues pour une détection de virus résistants plus précise et sensible que les analyses connues, notamment par la prise en compte des mutation compensatoires intervenant dans des séquences nucléotidiques autres que celles codant pour la cible du médicament antiviral.
PCT/GB2000/001639 1999-04-28 2000-04-28 Analyse amelioree et ses reactifs WO2000066774A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU45867/00A AU4586700A (en) 1999-04-28 2000-04-28 Improved assay and reagents therefor
EP00927464A EP1226270A2 (fr) 1999-04-28 2000-04-28 Analyse amelioree et ses reactifs
JP2000615396A JP2002542804A (ja) 1999-04-28 2000-04-28 改良されたアッセイとその試薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9909793.3 1999-04-28
GBGB9909793.3A GB9909793D0 (en) 1999-04-28 1999-04-28 Improved assay and reagents therefor

Publications (2)

Publication Number Publication Date
WO2000066774A2 WO2000066774A2 (fr) 2000-11-09
WO2000066774A3 true WO2000066774A3 (fr) 2002-05-23

Family

ID=10852424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001639 WO2000066774A2 (fr) 1999-04-28 2000-04-28 Analyse amelioree et ses reactifs

Country Status (5)

Country Link
EP (1) EP1226270A2 (fr)
JP (1) JP2002542804A (fr)
AU (1) AU4586700A (fr)
GB (1) GB9909793D0 (fr)
WO (1) WO2000066774A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
JP2005500003A (ja) * 2000-11-10 2005-01-06 バイオオーリアンス ファーマ ヒト免疫不全ウイルス（ｈｉｖ）の表現型特性の新規な分析法
FR2829506B1 (fr) * 2001-03-23 2006-05-19 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(hiv)
FR2829501B1 (fr) * 2001-03-23 2006-03-03 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829503B1 (fr) * 2001-03-23 2007-06-01 Bioalliance Pharma Nouvelee methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829502B1 (fr) * 2001-03-23 2006-01-13 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
WO2007080874A1 (fr) * 2006-01-10 2007-07-19 Meiji Seika Kaisha, Ltd. Fragment genetique mutant de staphylocoque faiblement sensible à un glycopeptide et son usage
AU2013245832A1 (en) * 2012-04-12 2014-11-27 Zeus Scientific, Inc. Methods for measuring polymerase activity useful for sensitive, quantitative measurements of any polymerase extension activity and for determining the presence of viable cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073511A1 (fr) * 1999-05-28 2000-12-07 Virco Nv Nouveaux profils mutationnels dans la transcriptase inverse du vih-1 en relation avec une pharmacoresistance phenotypique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073511A1 (fr) * 1999-05-28 2000-12-07 Virco Nv Nouveaux profils mutationnels dans la transcriptase inverse du vih-1 en relation avec une pharmacoresistance phenotypique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARRIE KIMBERLY A ET AL: "Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.", VIROLOGY, vol. 219, no. 2, 1996, pages 407 - 416, XP002178386, ISSN: 0042-6822 *
CARRILLO ALEJANDRO ET AL: "In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.", JOURNAL OF VIROLOGY, vol. 72, no. 9, 1998, pages 7532 - 7541, XP002178385, ISSN: 0022-538X *
HERTOGS KURT ET AL: "A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 2, February 1998 (1998-02-01), pages 269 - 276, XP000946883, ISSN: 0066-4804 *
MARTINEZ-PICADO JAVIER ET AL: "Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, no. 9, 1999, pages 2943 - 2951, XP000886935, ISSN: 0095-1137 *

Also Published As

Publication number Publication date
WO2000066774A2 (fr) 2000-11-09
EP1226270A2 (fr) 2002-07-31
GB9909793D0 (en) 1999-06-23
AU4586700A (en) 2000-11-17
JP2002542804A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
Daniloski et al. The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types
Qu et al. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy
Zipeto et al. Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes
US11125743B2 (en) Detection of norovirus using norovirus-specific toehold switches
Huang et al. dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation
WO2007016275A3 (fr) Procedes et compositions pour detecter le virus bk
JP2009515551A (ja) インフルエンザａウイルスの検出方法およびそのためのキット
CA2539703A1 (fr) Detection du papillomavirus humain faisant appel a des dosages biologiques de structures a clivage invasif enter the french title here.
Hamatake et al. A functional interaction of ICP8, the herpes simplex virus single-stranded DNA-binding protein, and the helicase-primase complex that is dependent on the presence of the UL8 subunit
Rola et al. The detection of bovine leukemia virus proviral DNA by PCR–ELISA
Lindh et al. Genotyping of hepatitis C virus by Taqman real-time PCR
WO2000066774A3 (fr) Analyse amelioree et ses reactifs
Li et al. The epitope study on the SARS-CoV nucleocapsid protein
Deol et al. CRISPR use in diagnosis and therapy for COVID-19
Rybicka et al. Current molecular methods for the detection of hepatitis B virus quasispecies
Yan et al. A one-step fluorescent biosensing strategy for highly sensitive detection of HIV-related DNA based on strand displacement amplification and DNAzymes
Shahni et al. Dual Detection of Hepatitis B and C Viruses Using CRISPR‐Cas Systems and Lateral Flow Assay
WO2006091757A3 (fr) Detection du virus de la bursite infectieuse tres virulent
WO2001079542A3 (fr) Essai de phenotypage et reactifs y relatifs
Idrees et al. Evaluation of three different hepatitis C virus typing methods for detection of mixed‐genotype infections
Müller et al. A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region
Wilber Branched DNA for quantification of viral load
Dietz et al. Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy
Ren et al. A strategy for searching antigenic regions in the SARS-CoV spike protein
Sultana et al. BRET-based biosensors for SARS-CoV-2 oligonucleotide detection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000927464

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615396

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10009754

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000927464

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000927464

Country of ref document: EP